Morningstar Acciones

三生制药 01530

Último Precio
6,05
Cambio del día
0,22|3,77%

a 25/04/2024
16:09:08 HKT | HKD  Minimum 15 Minutes Delay.

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
6,04 - 6,055,70 - 6,1314.719.65917.456.31414,76Bil
Último Cierre52 Week RangeP/BeneficioDividendo %ISIN
5,834,91 - 8,108,691,72KYG8875G1029

Cotización 3SBio Inc

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202020212022
More...
Cuenta de Resultados
Ingresos5.587,646.382,016.859,43
Operating Income1.536,951.776,472.017,15
Resultado Neto835,791.651,251.914,89
Beneficio Básico por Acción0,330,650,78
Num Medio Acciones diluidas en circulación2.7512.7702.648
Balance
Activo Corriente6.679,917.790,709.760,93
Activos no corrientes10.998,2911.421,8812.227,78
Total Activo 17.678,2019.212,5821.988,70
Pasivo corriente1.450,921.419,991.793,93
Total Pasivo---
Total Equity10.689,3112.227,4512.962,67
Flujo de Caja
Flujo de caja operativo1.344,561.578,352.180,28
Inversiones de Capital-981,47-1.145,77-973,73
Flujo de Caja Libre363,09432,571.206,54

En millones, excepto "EPS básico". Currency is CNY.

Perfil de la compañía

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

Sector

Atención sanitaria

Industria

Biotecnología

Estilo de acciones

Media-Valor

Fin Ejercicio Fiscal

diciembre

Empleados

5.411
Datos destacados
More...
Precio/Beneficio 12 m-
Precio/Valor contable0,94
Price/Sales TTM-
Crec Ingresos (media 3 a)8,85
Crec BPA (media 3 a)-
Margen operativo29,41
Margen neto27,92
ROE 12 m15,20
Deuda/Fondos propios0,32
Dividendos
AntLatest
Declared Date21/03/2320/03/24
Ex-Div27/06/2322/07/24
Paid11/07/2305/08/24
Amnt0,100,25
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. Reservados todos los derechos.

Términos de uso        Política Privacidad        Cookie Settings        Aviso Legal